VERAXA Biotech Shared BiTAC-ADC Proof-of-Concept Data

The company demonstrated tumor-specific response and reduced volume in breast cancer models during the World ADC Congress.

Updated on Oct. 13, 2026 in Biotech

VERAXA Biotech Shared BiTAC-ADC Proof-of-Concept Data

Live Poll

Is the development of safer, more precise cancer treatments moving fast enough for patients?

VERAXA Biotech presented in vivo proof-of-concept data for its BiTAC-ADC technology at the 17th World ADC Congress. The findings showed significant tumor regression in a xenograft breast cancer model.

Why it matters

This technology aims to improve cancer treatment safety by ensuring active toxins are only released upon internalization into tumor cells. By utilizing systemically inactive prodrugs, the strategy seeks to prevent off-target toxicity in the systemic periphery.

The BiTAC-ADC technology uses two complementary components that target separate tumor-associated antigens. These prodrugs remain inactive until they co-target the tumor site to trigger toxin release.

The players

VERAXA Biotech

A Zurich-based biotechnology company that develops advanced antibody-drug conjugates and proprietary therapeutic platforms.

World ADC Congress

An annual industry event that brings together pharmaceutical and biotech leaders to discuss the latest advancements in antibody-drug conjugate research.

The details

The treatment process requires two separate antibodies to target tumor-associated antigens simultaneously before becoming active. Researchers observed tumor reduction and regression in the test model at a single dose of 3 mg/kg.

October 13, 2026: VERAXA Biotech presented its latest data at the World ADC Congress in San Diego.

The Tech Race

This development represents a shift toward more precise oncology treatments that limit systemic exposure. It pushes the boundaries of existing antibody-drug conjugates by replacing broad-spectrum delivery with dual-target requirements.

While the technology is currently in the preclinical stage, it could eventually offer cancer patients treatments with fewer systemic side effects. Future clinical developments will determine when or if this platform enters the standard of care for oncology patients.

The takeaway

The BiTAC-ADC platform highlights a growing focus on dual-target specificity to minimize healthy tissue damage in cancer therapy. Researchers will continue to monitor how these dual-antibody systems perform as they transition from laboratory models to clinical applications.